Skip to main content

Efficacy in Children (1-11 Years)

DUPIXENT was studied across histologic, endoscopic,
and SYMPTOMATIC endpoints up to 52 weeks1,2

Not actual patient.

Not actual patient.

DUPIXENT DEMONSTRATED HISTOLOGIC REMISSION
IN CHILDREN AGED 1-11 YEARS1,2

HISTOLOGIC REMISSION ACHIEVED: 66% AT WEEK 16 AND 53% AT WEEK 52

Results are descriptive in the extended active treatment period at Week 52. Definitive conclusions cannot be made due to limitations associated with extended active treatment design, including lack of comparator arm and decreasing sample size.

Peak Esophageal
Intraepithelial
Eosinophil Count3,4

Used to confirm diagnosis and determine treatment response. Histologic data
are reported as the percentage of patients achieving the defined EOS threshold.

EOS, eosinophil: EOS/HPF, eosinophils per high-power field.

CHANGES IN ENDOSCOPIC FEATURES WERE OBSERVED

Improvements in EREFS total scores were observed
at Weeks 16 and 52 with DUPIXENT1,2

Reduction in EREFS
total scorea

Thresholds for clinically meaningful changes in EREFS scores have not been established. Results are descriptive in the extended active treatment period at Week 52. Definitive conclusions cannot be made due to limitations associated with extended active treatment design, including lack of comparator arm and decreasing sample size.

aReductions indicate improvements in score.

Endoscopic
Reference Score
(EREFS)3

EREFS is a clinician-reported rating of the severity of 5 endoscopic features:
edema, rings, exudates, furrows, and stricture.

DECREASE IN SIGNS AND SYMPTOMS WERE REPORTED BY CAREGIVERS1,2

Decrease in the number of days with ≥1 sign or symptom of EoE via
LSM change in PESQ-C1,2,b

Definitive conclusions cannot be made. Numerical improvements were observed at Week 16 and maintained for 52 weeks. Results are descriptive at Week 52 due to limitations associated with extended active treatment design, including lack of comparator arm and decreased sample size.

bBaseline number of days with EoE symptoms out of a 14-day period was 6.0 days in the DUPIXENT arm and 6.9 days in the placebo arm.2

PESQ-C measures the presence of signs and symptoms of EoE in children2,3

PESQ-C is a novel questionnaire designed with expert guidance to recognize
8 distinct signs and symptoms of EoE over a 14-day period by caregivers:

Stomach pain
Heartburn
Acid reflux
Regurgitation
Vomiting
Difficulty
swallowing
Food getting
stuck
Food refusal
  • Caregiver responses reflect what their child has told them, what they have directly observed, and/or what another caregiver has told them
  • Total score ranges from 0 to 1. For example, if the patient has 7 days of symptoms over the 14-day period, their total score is
    0.5 (calculated by 7 ÷ 14)

CHANGES IN BODY WEIGHT FOR AGE PERCENTILE WERE SEEN2

CHANGES IN BODY WEIGHT FOR AGE PERCENTILEc

Results are descriptive. Definitive conclusions cannot be made due to the exploratory nature of the results at Week 16, and lack of comparator arm and decreasing sample size at Week 52.

c Body weight for age percentile, standardized by gender and age, is used to assess a child's weight compared to their peers.

Contact a Field Representative

Connect with a DUPIXENT Field Representative to get answers to your
product-related questions.

CONTACT A REP